Smartwatch chargers sold on Amazon recalled in Canada over fire risk
The recalled QTHN Smartwatch Chargers could overheat, the agency said in a recall notice, adding the recalled charges are a white USB-C model with the model number PD2001.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
10 hours ago
Canadians could get more affordable version of Ozempic in early 2026. Here's how
Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as January. Ozempic is a social media darling — with celebrities singing its praises and people posting about major weight loss. But a patient can pay $400 a month for such medications, says Dr. Sanjeev Sockalingam, Obesity Canada's scientific director and a professor of psychiatry at the University of Toronto. He says his patients have been frustrated and disappointed by the prohibitive cost. But now, several companies say they intend to market cheaper versions of such drugs. Here's what medical experts say: What are these medications? Injectable prescription drugs, sold as Ozempic and Wegovy, and the pill Rybelsus all contain the ingredient semaglutide. This class of medication, known as glucagon-like peptide-1 agonists (GLP-1s), regulate blood sugar levels and appetite. Health Canada previously approved Ozempic to treat diabetes and Wegovy for weight loss. Nearly 33 per cent of Canadians (10.6 million people) were obese (new window) in 2023, according to a recent study. How much could the price come down? Novo Nordisk, maker of Ozempic and Wegovy, will effectively lose its price protection on those drugs in Canada in January, opening the door to generic versions. Mina Tadrous, an associate professor who evaluates pharmaceutical prices at the University of Toronto, says three or four companies have them in development or are starting the paperwork. Tadrous says the number of companies affects pricing. The classic framework is that if you only have one, it comes down from the list price to 75 per cent, Tadrous said. If we have two, it goes down to 50 per cent and if we have three it hits 25 per cent. Three manufacturers could bring the price down to $100 from $400 for the same strength of semaglutide product, Tadrous estimates. Have the generic medications been approved? Not yet. Health Canada needs to consider each company's application to make and sell generic versions of the injectable medication, known as a biosimilar. Since they won't require new clinical trials, they could be available within weeks of Health Canada's approval — grandfathered in, based on the original trials, says Sockalingam. It's really about the equivalency of the medication in terms of its availability in the body and its metabolism. Will insurance cover them? Semaglutide is already listed (new window) on the Ontario drug formulary — a list of publicly covered medications for those over age 65, people living in long-term care homes, and for people receiving Ontario Works or disability payments. That means as soon as a generic form is available, those on public drug insurance plans could switch to it, and private insurance plans like those offered by employers likely will do the same, Tadrous says. Dr. Kaberi Dasgupta, a professor of medicine at McGill University and a researcher, says this would be good news for people who have excess weight and resulting complications but who can't currently afford the branded medications. Generic versions will open the door for many more people, Dasgupta said. Mina Tadrous says if there are three manufacturers of generic semaglutide in Canada, it could bring the price down to $100. Photo: CBC / Craig Chivers What's involved in taking these medications? Dasgupta says it's important for people taking semaglutide to have it prescribed by a physician and then monitored. We should be insisting on having publicly accessible good diet and physical activity supports because we live in a society where people are gaining more and more weight, Dasgupta said. In England, for example, semaglutide is recommended with at least 13 hours of counselling on diet and physical activity. What about drug shortages? Because some medications also treat Type 2 diabetes, doctors and health-care policy experts continue to watch supply chains to prevent shortages. Dr. Harpreet Bajaj, an endocrinologist with LMC Healthcare in Brampton, Ont., recalls many times when patients with diabetes had to go off Ozempic or other GLP-1 medications because none was available. Having a biosimilar, which is made by an entirely new pharmaceutical company and maybe … made in a more cost-effective way would also relieve some pressures on any future shortages that we might expect, Bajaj said. Dasgupta, who also treats diabetes, said in her experience in Quebec, sometimes the medication is more accessible through the province's publicly funded plan for those who fulfil the medical criteria than through some private insurers that focus more strongly on cost. Amina Zafar (new window) · CBC News · Journalist Amina Zafar covers medical sciences and health care for CBC. She contributes to CBC Health's Second Opinion, which won silver for best editorial newsletter at the 2024 Digital Publishing Awards. She holds an undergraduate degree in environmental science and a master's in journalism.
Cision Canada
12 hours ago
- Cision Canada
Health Canada Approves Lilly's Omvoh® (mirikizumab) for Crohn's Disease; New Citrate-Free Formulation Français
Omvoh ® is now indicated for both major forms of Inflammatory Bowel Disease (IBD) – ulcerative colitis (UC) and Crohn's disease (CD) In VIVID-1, Omvoh ® showed statistically significant and clinically meaningful efficacy across multiple endpoints compared with placebo in patients with moderately to severely active CD, meeting the coprimary composite endpoints and all major secondary endpoints. 3 Health Canada has also approved a new citrate-free formulation of Omvoh ® for subcutaneous injection, which contains the same active ingredients as the original Omvoh ®. TORONTO, July 15, 2025 /CNW/ - Eli Lilly Canada Inc. (Lilly Canada) announced today that Health Canada has approved Omvoh ® (mirikizumab) for CD, which will soon be available to patients in Canada. Omvoh ® is an interleukin-23p19 antagonist for the treatment of adult patients with moderately to severely active CD who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic treatment. 1 Health Canada has also approved a new citrate-free formulation of Omvoh ® for subcutaneous injection, for the existing UC indication, as well as the new CD indication. "We are pleased to see that Omvoh ® will now be able to provide people living with moderately to severely active CD an effective and safe option for treatment," said Mathilde Merlet, President and General Manager of Lilly Canada. "With this additional indication, we are reinforcing our commitment to helping more of the IBD community. Additionally, we are proud to be able to introduce a new citrate-free formulation, which we hope will improve the patient experience, while offering the same quality, efficacy, and safety that patients are accustomed to." The authorization of Omvoh ® for CD was based on results from the VIVID-1 clinical study, which included over 1,000 adults. In VIVID-1, mirikizumab showed statistically significant and clinically meaningful efficacy across multiple endpoints compared with placebo in patients with moderately-to-severely active CD, meeting the coprimary composite endpoints and all major secondary endpoints. The coprimary composite endpoints included patient-reported outcome (PRO) clinical response at week 12 and endoscopic response at week 52 (endoscopic response-composite), and PRO clinical response at week 12 and Crohn's Disease Activity Index (CDAI) clinical remission at week 52 (CDAI clinical remission-composite). Endoscopic response-composite was reached in 220 (38%) of 579 patients on mirikizumab versus 18 (9%) of 199 patients on placebo; CDAI clinical remission-composite was reached in 263 (45%) of 579 patients on mirikizumab versus 39 (20%) of 199 patients on placebo. Statistical significance was also observed in subgroups with and without failure to biological therapies for coprimary endpoints and most major secondary endpoints. 3 The Community Reacts: Sylvain Chiasson, Interim President & CEO of Crohn's and Colitis Canada: "Crohn's and Colitis Canada always welcomes new treatments for people with CD in Canada. CD is a chronic autoimmune disease where the immune system attacks the gastrointestinal system. CD is a complex disease that is debilitating, leads to hospitalizations and surgeries, and has a tremendous impact on the quality of life for the approximately 162,000 Canadians living with this disease. Because of the disease's complexity, not all people with CD respond in the same way to the available treatments. So, it is welcome news for Crohn's and Colitis Canada when there is a new therapy available for people with CD." Gail Attara, Chief Executive Officer of the Gastrointestinal Society ( "We are so pleased to learn that Health Canada has approved a CD indication for Omvoh (mirikizumab). Compared to other inflammatory conditions, CD has very few medications, so the introduction of Omvoh's expanded use as a new option is excellent news for the IBD community." Dr. John Marshall, Professor of Medicine, and Director of the Division of Gastroenterology at McMaster University: "It is exciting to see a new and highly effective therapy being made available for people living with CD. Clinical trials have shown mirikizumab to be both safe and effective, and this will be an appealing treatment option for patients who are new to biologic therapies, or those who have not responded adequately to previous advanced therapies." About the VIVID-1 Clinical Trial Program VIVID-1 was a Phase 3, randomized, double-blind, treat-through study that evaluated the safety and efficacy of mirikizumab compared with placebo and an active control (ustekinumab) in adults with moderately to severely active CD. Patients randomized to mirikizumab were administered 900 mg of mirikizumab intravenously every four weeks from Weeks 0-8, then 300 mg subcutaneously every four weeks from Weeks 12-52. In this study, 49% of patients treated with mirikizumab or placebo had experienced a prior biologic failure. 2 The overall safety profile of mirikizumab in patients with moderately to severely active CD was consistent with the known safety profile in patients with UC. The frequency of serious adverse events was greater in placebo than mirikizumab. The most common adverse events were upper respiratory tract infections, injection site reactions, headache, and rash. 1 About Omvoh ® Omvoh ® (mirikizumab) is an interleukin-23p19 (IL-23) antagonist indicated for the treatment of moderately to severely active UC and CD in adults. Omvoh ® selectively targets the p19 subunit of IL-23 and inhibits the IL-23 pathway. Inflammation due to overactivation of the IL-23 pathway plays a critical role in the pathogenesis of CD, a chronic, IBD associated with progressive bowel damage, disability and decreased health-related quality of life. For more information about Omvoh ®, please refer to the product monograph on About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. Lilly has been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Lilly's Canadian Affiliate, Eli Lilly Canada Inc. was established in 1938, the result of a research collaboration with scientists at the University of Toronto which eventually produced the world's first commercially available insulin. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more about Lilly Canada, visit or follow us on LinkedIn. Omvoh ® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
Global News
a day ago
- Global News
How Environment Canada shows air quality risk levels amid wildfires
Wildfire season is upon us once again, and smoke is reducing air quality through swaths of the country. Environment Canada suggests people check the Air Quality Health Index daily to determine how much time to spend outside. Here's how to interpret the index: How do I find out my local air quality reading? Environment Canada's air quality index is at Story continues below advertisement You can take a look at the ratings in communities across your province or territory. A rating of 1-3 is low risk, 4-6 is moderate risk, 7-10 is high risk and over 10 is very high risk. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy The risk designations can change regularly in the same community, Environment Canada says, so it's important to keep checking the air quality forecast. What do the risk ratings mean? Environment Canada, in consultation with Health Canada, has different recommendations for people especially at risk of suffering health problems when exposed to poor air quality compared to the general population. 'At risk' people include those with respiratory issues such as asthma, chronic obstructive pulmonary disease (COPD), pneumonia, as well those with as heart disease. Infants, young children, pregnant people and elderly people are also considered at higher risk. Story continues below advertisement The government agency lists the various health conditions that put you at higher risk at this website Here's how to interpret the Air Quality Health Index guidance: 'Low risk' means everyone can safely be outdoors. 5:15 Improving air quality in the summer 'Moderate risk' means the general population doesn't need to change their usual outdoor activities unless they have symptoms such as coughing and throat irritation. But people at risk should 'consider reducing or rescheduling strenuous activities outdoors.' 'High risk' means those at risk should reduce or reschedule strenuous activities outdoors. Children and seniors should 'take it easy.' The general population should consider reducing or rescheduling strenuous activities if they start coughing or their throats become irritated. 'Very high risk' means everyone should reduce or reschedule strenuous activities. People at risk should avoid outdoor activities altogether.
